Stay updated with breaking news from Gerhard ehninger. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mediziner und Politiker fordern Corona-Impfung bei Kindern | Freie Presse freiepresse.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freiepresse.de Daily Mail and Mail on Sunday newspapers.
"Dresdner Stimmen": Menschheit wird Covid-19 nicht mehr los – aber es gibt Hoffnung dnn.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dnn.de Daily Mail and Mail on Sunday newspapers.
Share this article DRESDEN, Germany, March 2, 2021 /PRNewswire/ GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced the publication of clinical data obtained from the ongoing Phase I study of their rapidly switchable UniCAR platform lead asset, UniCAR-T-CD123, in relapsed/refractory acute myeloid leukemia (rrAML), in the journal Blood . The interim data of UniCAR-T-CD123 in rrAML, published online ahead of print as a letter in Blood (Wermke et al. 2021, https://doi.org/10.1182/blood.2020009759), demonstrate that UniCAR-T-CD123 in rrAML is well-tolerated with rapid recovery of hematopoiesis and encouraging early efficacy. The Blood publication nicely underpins the clinical advantages of our rapidly switchable UniCAR platform, which have also been recently presented at the 3 ....
Share this article DRESDEN, Germany, Feb. 3, 2021 /PRNewswire/ GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced interim data from the ongoing Phase I study of their lead asset UniCAR-T-CD123 in relapsed/refractory acute myeloid leukemia (rrAML) at the Virtual 3 rd EHA-EBMT European CAR-T-Cell Meeting, which is held from February 04-06, 2021. The data are being presented as oral presentation by Dr. Martin Wermke, University Hospital Dresden, Germany (February 05, 12:20 CET) and as a poster presentation by Dr. Sabrina Kraus, University Hospital Würzburg, Germany (Abstract 68). These clinical results present a promising step forward as we continue to evaluate the safety and efficacy of UniCAR-T-CD123, said Professor Gerhard Ehninger, Chief Medical Officer of GEMoaB. We are highly encouraged by the fact that UniCAR-T-CD123 has demonstrated a favorable safety and efficacy ....